Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC
Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC
Active, not recruiting · NCT03813394 · Registry updated 2024-11-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC | DNA Virus Infections, Epstein-Barr virus infection, Head and Neck Neoplasms, Herpesviridae infectious disease, Infections, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, Tumor Virus Infections, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease, viral infectious disease | Active, not recruiting | Phase 1 / Phase 2 | 2024-11-22 | NCT03813394 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
| National University Hospital, Singapore | 120 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| National University Hospital | Singapore | Singapore | 46 |